Summary & Overview
CPT 96372: Therapeutic, Prophylactic, or Diagnostic Injection Administration
CPT code 96372 is a widely utilized billing code for the administration of therapeutic, prophylactic, or diagnostic injections by subcutaneous or intramuscular routes. This procedure is a cornerstone in outpatient care, enabling clinicians to deliver medications and preventive treatments efficiently in office and hospital settings. The code is relevant across multiple specialties, including hematology, oncology, and family medicine, and is frequently used for services such as HIV pre-exposure prophylaxis and other preventive interventions.
Major national payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare. The publication provides a comprehensive overview of payer coverage, policy updates, and clinical benchmarks related to 96372. Readers will gain insight into the clinical context of injection administration, typical sites of service, and the role of this code in routine and preventive care. The summary also highlights related codes and modifiers that may impact billing and reimbursement, offering a clear understanding of how 96372 fits into broader medical billing practices.
This article is designed to inform healthcare professionals, billing specialists, and policy analysts about the national landscape for 96372, including payer policies, clinical applications, and coding nuances.
CPT Code Overview
CPT code 96372 is used to report the administration of a therapeutic, prophylactic, or diagnostic injection via subcutaneous or intramuscular route. This code applies to injection administration services that are not related to chemotherapy and are performed in settings such as a physician's office or outpatient hospital. The procedure involves delivering a specified substance or drug directly into the patient's tissue, supporting a range of clinical needs from preventive care to diagnostic evaluation.
Clinical & Coding Specifications
Clinical Context
A patient presents to a clinic for a scheduled injection of a therapeutic or prophylactic medication, such as HIV pre-exposure prophylaxis. The provider reviews the patient's medical history and confirms the indication for the injection. The medication is prepared and administered either subcutaneously or intramuscularly in the office setting. Documentation includes the substance injected, route, and site. The patient is monitored briefly for any adverse reactions before discharge.
Coding Specifications
- Modifier
59: Used to indicate a distinct procedural service, such as when multiple separate injections are performed during the same encounter and need to be reported individually.
| Modifier Code | Description |
|---|---|
59 | Distinct Procedural Service |
- Provider Taxonomies:
| Taxonomy Code | Specialty Name |
|---|---|
207RG0100X | Hematology & Oncology |
208D00000X | Family Medicine |
Related Diagnoses
-
Z29.81: Encounter for HIV pre‑exposure prophylaxis- Relevant when the injection is for preventive medication against HIV, such as PrEP.
-
Z20.6: Contact with and (suspected) exposure to human immunodeficiency virus [HIV]- Used when the injection is indicated due to potential or suspected exposure to HIV, supporting the medical necessity for prophylactic treatment.
Related CPT Codes
96377: Application of on-body injector (includes cannula insertion) for timed subcutaneous injection (used instead of96372for Onpro/ONBODY device)
Clinical Relationship:
96377is used when the injection is administered via an on-body injector device, rather than a manual subcutaneous or intramuscular injection as described by96372.- These codes are alternatives depending on the method of drug delivery. They are not typically used together in the same encounter.
National Reimbursement Benchmarks
Nationally, the mean rate for CPT code 96372 is highest among commercial payers, with Cigna at $27.92 and Aetna at $26.73. The average commercial benchmark (BUCA) stands at $24.44, notably higher than the Medicare mean rate of $15.88. This highlights a substantial gap between commercial and Medicare reimbursement levels for this procedure.
Rate dispersion varies across payers. Medicare exhibits the tightest range, with its 75th and 25th percentiles nearly identical ($16.00 vs $15.00), indicating minimal variation. In contrast, Cigna shows the widest spread, with a difference of $16.00 between its 75th and 25th percentiles ($34.00 vs $18.00). Other commercial payers such as Aetna and UnitedHealth Group also display broader ranges, reflecting greater variability in rates.
The table and chart below present a detailed breakdown of national benchmarks for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.